Your session is about to expire
← Back to Search
Ruxolitinib cream for Vitiligo
Study Summary
This trial will study how well ruxolitinib cream works to treat vitiligo by measuring changes in biomarkers.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical issues is Ruxolitinib cream commonly used to address?
"Ruxolitinib cream is the preferred treatment for polycythemia vera. Other conditions it may be prescribed to manage include hydroxyurea-resistant or -intolerant polycythemia, as well as primary myelofibrosis."
What is the aggregate number of individuals partaking in this clinical experiment?
"Unfortunately, this trial has ceased to accept new participants. The initial posting was on June 23rd 2021 and the final update happened on September 14th 2022. However, if one is interested in similar trials there are 37 vitiligo studies recruiting now and 97 for Ruxolitinib cream which remain open."
Is there still an opportunity for participants to join this research endeavor?
"Unfortunately, this clinical trial is not presently enrolling participants. It was first published on June 23rd 2021 and updated most recently on September 14th 2022. On the other hand, if you are still seeking a medical trial to participate in, there are currently 37 studies accepting vitiligo patients and 97 recruiting for Ruxolitinib cream."
What is the current extent of this clinical trial's implementation in hospitals?
"Eleven medical centres are involved in this trial, such as First Oc Dermatology located in Fountain Valley, UC Irvine situated at Irvine, and JRB Research Inc found in Ottawa. The other eight sites have yet to be revealed."
Are there any analogous research endeavors concerning Ruxolitinib cream?
"First studied in 2002 at the NIH Clinical Center, ruxolitinib cream has been subject to 110 clinical trials. Currently 97 of these studies are ongoing with a significant number occurring out of Fountain Valley, California."
What potential harms may arise from using Ruxolitinib cream?
"Our assessment of the safety of Ruxolitinib cream was a 2, as it is still in Phase 2 and thus there are some data points that support its security but none that suggest efficacy."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Mount Sinai Hospital: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger